Home Press Releases Cannabis Kali-Extracts Brand Name Gains Momentum In Cannabis Extraction Market

Kali-Extracts Brand Name Gains Momentum In Cannabis Extraction Market

Kali-Extracts Brand Name Gains Momentum In Cannabis Extraction Market

KALY – Kali-Extracts Brand Name Gains Momentum In Cannabis Extraction Market

Dallas, TX — June 4, 2019 — InvestorsHub NewsWire — Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced an agreement with a New York State Licensed Hemp Cultivation Operation anticipated to generate an estimated $5 million in revenue for KALY.  A key aspect of why the New York State Licensed Hemp Cultivation Operation selected Kali-Extracts is because of Kali-Extracts growing brand recognition for high quality extracts.  KALY owns and operates a U.S. Patented Cannabis Extraction Process.  The company is advancing biotechnology research for the future production of cannabis extract centric pharmaceuticals and at the same time, the company is currently generating revenue from the sale of CBD infused consumer products.  The New York State Licensed Hemp Cultivation Operation believes the consignment of its hemp crop to KALY to extract and sell CBD extract under the Kali-Extracts brand name will drive higher volume sales with higher profitability under the Kali-Extracts brand name then if they went it alone.  KALY management believes this first consignment and extraction contract is just the beginning and that the company can sign multiple similar contracts which it can efficiently serve with its mobile extraction lab.

KALY is biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from a proprietary cannabinoid product platform in a broad range of disease areas.  In the fourth quarter of last year, 2018, KALY acquired NCM Biotech (NCMB).  In NCMB’s four years of operations, the company has established a leading position in the development of plant-derived cannabinoid therapeutics through a proven drug discovery and patented development process.  The resulting intellectual property portfolio and the established regulatory and manufacturing expertise have created a significant opportunity.  KALY has a deep pipeline of cannabinoid product candidates including four distinct compounds.  KALY has completed the first stage of clinical development and testing for a Chronic Obstructive Pulmonary Disease (COPD) therapy and is currently conducting phase one development and trials for compounds targeting Cancer Pain Management, Type 2 Diabetes and Epilepsy.

KALY is not relying on its biopharmaceutical development strategy alone to insure the company’s long-term success.  With the popularity of cannabis extracts for infusion into various consumer products, KALY’s patented extraction process offers arguably the highest quality extract to the infusion market.  Drawing on KALY’s patented cannabis extraction expertise, in addition to winning the $5 million extraction contract announced today, KALY has partnered with Puration (USOTC: PURA) to lend its extraction expertise in the production of EVERx CBD Sports Water, the leading CBD infused beverage for the sports nutrition market.  KALY has also introduced its own CBD confections line, Hemp4mula with CBD infused gum already on the market and gummies on the way.  Hemp4mula is available on the Ecommerce site USMJ.com hosted by North American Cannabis Holdings, Inc. (USOTC: USMJ) (aka USMJ).  KALY’s non-pharmaceutical extraction revenue strategy offers a business line that can stand alone, and at the same time provide KALY with the long-term staying power to bring its cannabis extract biopharmaceutical products to market. 

To learn more about the company visit https://www.kali-extracts.com/

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company’s actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.


Frederick Ferri
[email protected]

(214) 210-0459